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Berberine is a plant alkaloid with multiple pharmacological actions, including antidiarrhoeal
activity and has been shown to inhibit Cl− secretion in distal colon. The aims of this study
were to determine themolecular signalingmechanisms of action of berberine on Cl− secre-
tion and the ion transporter targets. Monolayers of T84 human colonic carcinoma cells
grown in permeable supports were placed in Ussing chambers and short-circuit current
measured in response to secretagogues and berberine.Whole-cell current recordingswere
performed in T84 cells using the patch-clamp technique. Berberine decreased forskolin-
induced short-circuit current in a concentration-dependent manner (IC50 80± 8μM). In
apically permeabilized monolayers and whole-cell current recordings, berberine inhibited a
cAMP-dependent and chromanol 293B-sensitive basolateralmembraneK+ current by 88%,
suggesting inhibition of KCNQ1 K+ channels. Berberine did not affect either apical Cl− con-
ductance or basolateral Na+–K+-ATPase activity. Berberine stimulated p38 MAPK, PKCα
and PKA, but had no effect on p42/p44 MAPK and PKCδ. However, berberine pre-treatment
prevented stimulation of p42/p44 MAPK by epidermal growth factor. The inhibitory effect
of berberine on Cl− secretion was partially blocked by HBDDE (∼65%), an inhibitor of PKCα
and to a smaller extent by inhibition of p38 MAPK with SB202190 (∼15%). Berberine treat-
ment induced an increase in association betweenPKCα andPKAwith KCNQ1and produced
phosphorylation of the channel. We conclude that berberine exerts its inhibitory effect on
colonic Cl− secretion through inhibition of basolateral KCNQ1 channels responsible for K+
recycling via a PKCα-dependent pathway.
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INTRODUCTION
Berberine is a benzodioxoquinolone plant alkaloid isolated from
several species of Berberis and Coptis. In Chinese and Hindu med-
icine, berberine has been used to treat gastroenteritis, abdominal
pain, and diarrhea for over two millennia. Various pharmacolog-
ical actions have been described for berberine, including antimi-
crobial (Iwasa et al., 1998), anti-inﬂammatory (Ivanovska and
Philipov, 1996), and cardiovascular effects (Lau et al., 2001). In
several small-scale clinical trials, berberine has proven effective in
the treatment of secretory diarrhea (Rabbani et al., 1987; Tang
and Eisenbrand, 1992). Although its therapeutic beneﬁt has been
attributed in part to its antimicrobial and antimotility properties
(Yamamoto et al., 1993), berberine has been shown to prevent
epithelial electrolyte secretion in vitro in rabbit and rat intestine
(Guandalini et al., 1987; Taylor and Baird, 1995).
Diarrheal diseases continue to be a major cause of morbid-
ity and mortality in children and elderly people throughout the
world. Oral rehydration therapy remains the mainstay of treat-
ment for diarrhea (Taylor and Greenough, 1989). However, in
recent years signiﬁcant effort has been made in the search for
antisecretory drugs that will directly inhibit secretory processes
within the enterocytes (Ma et al., 2002; Farthing, 2006).
Activated Cl− secretion from the intestinal crypt is thought
to play a major role in secretory diarrhea of several aetiologies
(Field, 2003). The generation of the electrochemical driving force
required for Cl− secretion by crypt epithelial cells depends on
their ability to accumulate intracellular Cl− ions to concentra-
tions greater than their electrochemical equilibrium (Barrett and
Keely, 2000; Kunzelmann and Mall, 2002). Cl− enters the cell
across the basolateral membrane through the activity of Na+–
K+-2Cl− cotransporters. The cotransporter is, in turn, driven by
a strong inwardly directed electrochemical Na+ gradient estab-
lished by the basolaterally located Na+–K+-ATPase. In order to
maintain the membrane potential at rest and during Cl− secre-
tion, both Na+ and K+ must be recycled out of the cell through
the basolateral membrane. The Na+–K+-ATPase serves to recycle
Na+,while basolateral potassium channels recycle K+ (Schultheiss
and Diener, 1998). The basolateral K+ conductance in intestinal
epithelial cells is formed by at least two different types of K+
channels, one activated by Ca2+-mobilizing secretagogues and the
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other by cAMP-dependent agonists (Heitzmann andWarth,2008).
Electrophysiological studies have revealed the latter to be KCNQ1,
a low conductance (1–3 pS) basolateral K+ channel, which is acti-
vated during cAMP-stimulated Cl− secretion and inhibited by
chromanol 293B and HMR-1556 (Schroeder et al., 2000; Robbins,
2001). As in all secretory epithelia, the channels and transporters
of the crypt epithelial cell must operate in concert to achieve vec-
torial ion transport. Therefore, blockade of speciﬁc basolateral
K+ conductance would be expected to inhibit the Cl− secretory
process.
The T84 cell line is a well-differentiated intestinal human car-
cinoma cell line proved to be a robust model for the study of
molecular mechanisms of intestinal secretion in close to 1,200
publications since the early 1980s (Dharmsathaphorn et al., 1984).
Previous studies usingT84 cells,grown to conﬂuence andmounted
in Ussing chambers, have shown that berberine decreased Cl−
secretion in a dose-dependent manner (Taylor and Baird, 1995).
More importantly, berberine attenuated the large Cl− secretory
current produced by agents that increase intracellular cAMP.How-
ever, the speciﬁc transport pathways responsible for the inhibitory
effect of berberine on Cl− secretion have not been identiﬁed.
Herein we report on a series of experiments designed to clar-
ify which epithelial transport processes are affected by berberine.
Using the short-circuit current technique, we studied the ability of
berberine to inhibit Cl− secretion induced by cAMP in T84 cells.
Using the pore-forming antibiotics nystatin and amphotericin B to
permeabilized the basolateral and apical membranes respectively,
we were able to isolate membrane currents and assess the effects of
berberine on (1) the apical membrane Cl− conductance, (2) the
basolateral membrane Na+–K+-ATPase activity, and (3) the baso-
lateralmembraneK+ conductance.Also,we explored the signaling
involved in the antisecretory action of berberine in particular the
role of protein kinases such as PKC, PKA, mitogen-activated pro-
tein kinase (MAPK), and membrane targets such as ion channels
and transporters. Our results indicate that berberine inhibits Cl−
secretion by decreasing the basolateral membrane K+ conduc-
tance and therefore K+ recycling necessary for the generation of
the favorable electrochemical gradient required for Cl− secretion.
MATERIALS AND METHODS
CELL CULTURE
T84 cells (American Type Culture Collection, Manassas, VA,
USA) were cultured in a 1:1 mixture of DMEM and Ham’s F-
12 supplemented with 10% fetal bovine serum, 1% non-essential
amino acids, 50 U·ml−1 penicillin, 0.05 mg·ml−1 streptomycin,
and grown onto Costar Snapwell culture inserts (Corning,Dublin,
Ireland) with an area of 1 cm2 for short-circuit current mea-
surements or onto 24 mm Costar Transwell ﬁlters (0.4 μm pore)
for protein assays. Experiments were conducted on conﬂuent
monolayers 8–12 days after culture onto the permeable supports.
TRANSEPITHELIAL TRANSPORT STUDIES
T84 cells were grown onto Snapwell inserts and mounted in Uss-
ing chambers (Physiologic Instruments, San Diego, CA, USA).
Transepithelial potential difference was clamped to zero using
an EVC-4000 voltage-clamp apparatus (World Precision Instru-
ments, UK). The transepithelial short-circuit current (I SC) was
recorded using Ag–AgCl electrodes in 3 M KCl agar bridges as
previously described (Condliffe et al., 2001). Transepithelial resis-
tance (Rt) was calculated by measuring the I SC resulting from 5-s
square voltage pulses (2 or 4 mV) imposed across the monolayer.
All preparations were allowed to equilibrate for 30 min before the
experiments were performed.Amiloride (50 μM)was added at the
start of the experiments to block Na+ absorption. All experiments
were performed at 37˚C. The I SC was deﬁned as positive for anion
ﬂow from the basolateral to apical chamber.
Speciﬁc apical Cl− channel conductance and basolateral
Na+/K+ pump and K+ channel conductances were isolated and
analyzed using a well-established technique consisting of selec-
tive membrane permeabilization using ionophores as previously
described (DuVall et al., 1998). To investigate the activity of apical
Cl− conductance in isolation, the basolateral membrane was per-
meabilized by addition of 200μg·ml−1 nystatin in the presence of
an apical to basolateral Cl− gradient. Forskolin was then added
to the apical and basolateral sides of the monolayers to activate
the cystic ﬁbrosis transmembrane conductance regulator (CFTR).
Under these conditions, the I SC represents the Cl− current (ICl)
as Cl− moves down its concentration gradient through the CFTR
channels in the apical plasma membrane.
To investigate the activity of basolateral Na+–K+-ATPase activ-
ity in isolation, the apical membrane was permeabilized by addi-
tion of 10μM amphotericin B. Na+–K+-ATPase activity was
examined in monolayers bathed with medium in which NaCl was
replaced by N -methyl-d-glutamine chloride, such that the ﬁnal
bath Na+ concentration was 25 mM on both sides of the mono-
layers. Under short-circuit conditions, the resulting current is due
to the transport of Na+ across the basolateral membrane by the
Na+–K+-ATPase (INa).
To investigate the activity of the basolateral K+ conductance in
isolation, the apical membrane was permeabilized by addition of
10μM amphotericin B in the presence of an apical to basolateral
K+ gradient. Ouabain (100μM) was added to the basolateral bath
to inhibit Na+–K+-ATPase. The resulting I SC is due to the move-
ment of K+ through channels in the basolateral membrane (IK).
The use of antibiotic-based ionophores to selectively permeabi-
lized epithelial membranes is a well-established electrophysiologi-
cal protocol since the 1980s to gain an insight into ion conductive
properties at the opposite unpermeabilized membrane. Antibiotic
ionophores used for transport studies are permselective for ions of
similar size with the exception of valinomycin for K+. The estab-
lishment of large transepithelial (transmembrane) ionic gradients
for the ion under study and the use of selective channel block-
ers aid in extracting the conductive properties of the particular
rheogenic ion transport pathway as was done in this study.
PATCH-CLAMP RECORDINGS
A small aliquot of Krebs solution containing single T84 cells was
transferred into a 1-ml superfusion chambermounted on the stage
of an inverted microscope (Nikon Diaphot). Patch pipettes were
prepared from capillary glass (GC150 F-10, Harvard Apparatus
Ltd., Edenbridge, UK) using a programmable horizontal puller
(DMZ-Universal Puller, Zeitz-Instruments GmbH, Munich, Ger-
many) and had a resistance of 3–6Ω when ﬁlled with the pipette
solution. The reference electrode was an Ag–AgCl wire in direct
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contact with the superfusion bath. Patch-clamp apparatus con-
sisted of a CV-203BU headstage (Axon Instruments Inc., Union
City, CA, USA) connected to an Axopatch 200B series ampliﬁer.
Experiments were performed using the whole-cell patch-clamp
conﬁguration and recorded membrane currents were ﬁltered at
1 kHz and digitized at 5 kHz. Membrane voltage was clamped
from −100 to +100 mV with ramps of 20 mV from an initial hold-
ing potential of −50 mV. The protocols for patch-clamp and data
analysis were established using pClamp 9.2 software (Axon Instru-
ments Inc.) running on a PC, and data were stored for subsequent
analysis. For patch-clamp measurements, the standard bath solu-
tion contained (in mM): NaCl 140, KCl 5.4, MgCl2 1, CaCl2 1.25,
glucose 12.2, and HEPES 10, buffered at pH 7.4 with NaOH. The
patch pipette solution contained (in mM): K-gluconate 95,KCl 30,
Na2HPO4 4.8, KH2PO4 1.2, EGTA 1, Ca-gluconate 0.73, MgCl2
1, Na2ATP 3, glucose 5 (pH 7.2). Drug actions were measured
only after steady-state conditions were reached. All patch-clamp
experiments were performed at 37˚C.
IMMUNOPRECIPITATION AND WESTERN BLOTTING
T84 cells were serum-starved for 24 h prior to treatment. Drugs
were added to the basolateral side of the cell monolayers for
the required time. After treatment cells were lysed and subjected
to standard 10% SDS-PAGE and Western blotting as previously
described (Dilly et al., 2004). Immunoblots were developed using
speciﬁc phospho-antibodies against human PKCα, PKCδ, p42/p44
MAPK, and p38 MAPK. Immunoprecipitation assays for KCNQ1
were carried out as previously described (Dilly et al., 2004).
PKA ASSAY
PKA activity was detected using the PepTag® assay for non-
radioactive detection of cAMP-dependent protein kinase. The kit
was used according to manufacturer’s instructions using 30 μg
of protein in each reaction http://www.promega.com/resources/
protocols/technical-bulletins/0/peptag-assay-for-nonradioactive-
detection-of-pkc-or-campdependent-protein-kinase-protocol/.
T84 cells were lysed by hypotonic shock on ice for 45 min (lysis
buffer: 20 mM tris, pH 7.4, 0.5% non-ident P-40, 250 mM NaCl,
3 mM EDTA, 3 mM EGTA, leupeptin 1μg/μl, 500 mM dithiothre-
itol, 5 mM phenylmethylsulfonyl ﬂuoride, complete mini EDTA-
free protease inhibitor mixture tablets (1 tablet/7 ml of lysis buffer;
Roche Applied Science) and phosphatase inhibitors.
STATISTICAL ANALYSIS
Densitometric analysis was performed using Genetools software
(Syngene, Cambridge, UK). Statistical analysis of the data was
obtained using paired t -test for analysis between two groups.
ANOVA and Tukeys post hoc test for multiple analyses. P-values
of 0.05 and less were considered to be signiﬁcant. Data are
expressed as mean ± SEM unless speciﬁcally stated to be from a
representative experiment.
MATERIALS
Phospho-PKCd/θ (Ser643/676), p44/p42 MAPK, phospho-p42/p44
MAPK (Thr202/Tyr204), and phospho-p38 MAPK (Thr180/Tyr182)
antibodies were from Cell Signaling Technologies (Hertfordshire,
UK). PKCα and PKAcI antibodies were from BD Trans-
duction Antibodies (NJ, USA). Phospho-PKCα (Ser657) anti-
body was from Upstate (Dublin, Ireland). KCNQ1 antibody
was from Santa Cruz (CA, USA). Chromanol 293B was
obtained from Tocris (Avonmouth, UK). Rottlerin, clotrimazole,
SB202190, and HBDDE were purchased from Calbiochem
(Nottingham, UK). (3R,4S)-(+)-N -[3-hydroxy-2,2-dimethyl-6-
(4,4,4-triﬂuorobutoxy)chroman-4-yl]-N -methylethanesulfonami
de (HMR-1556) was kindly provided by Dr. Uwe Gerlach (Aventis
Pharma Deutschland, Frankfurt-am-Main, Germany). All other
chemicals were purchased from Sigma-Aldrich (Dublin, Ireland).
All drugs were dissolved in DMSO or water as stock solutions
and diluted appropriately. The ﬁnal DMSO concentration was less
than 0.1%.
RESULTS
BERBERINE INHIBITS cAMP-STIMULATED Cl− SECRETION IN COLONIC
EPITHELIAL CELLS
Short-circuit current measurements across T84 monolayers under
basal conditions revealed a small I SC reﬂecting a low level of
Cl− secretion. When the epithelium was treated with forskolin
(10μM), the I SC rapidly increased from 4 ± 2 to 48± 6μA·cm−2
and remained signiﬁcantly elevated for over 30 min. Berberine
when added to the basolateral solution at the peak of the forskolin
response decreased the I SC (control 46± 5μA·cm−2, berber-
ine 5± 3μA·cm−2; n = 8, P < 0.01; Figure 1A). The inhibitory
FIGURE 1 | Effect of berberine on forskolin-induced Cl− secretion. (A)
Representative short-circuit current recording of the effect of berberine
(300μM) on forskolin-stimulated ISC in T84 cell monolayers. Drugs were
added at arrow and remained in the bathing solutions throughout the
experiment (B) Concentration-response curve for the antisecretory effect of
berberine on forskolin-stimulated ISC in T84 cell monolayers. Change in ISC
measured 15min post berberine application at different concentrations.
Values are mean±SEM n= 8 for each point.
www.frontiersin.org June 2011 | Volume 2 | Article 33 | 3
Alzamora et al. Berberine inhibition of KCNQ1 channels
effect of berberine on forskolin-induced Cl− secretion was
concentration-dependent between 10 and 300 μM with an IC50 of
80± 3μM (Figure 1B). No signiﬁcant effect on I SC was observed
when berberine was added in the absence of forskolin, however,
subsequent treatment with forskolin failed to increase I SC (not
shown). In approximately 75% of the experiments berberine-
induced a small and transient increase in I SC (Figure 1A). This
response was prevented by addition of BaCl2 (2 mM) to the apical
bath suggesting berberine also inhibits an apical K+ conduc-
tance responsible for K+ secretion (data not shown). Berberine
treatment for as long as 2 h did not decrease the transepithelial
resistance Rt compared to vehicle controls, suggesting that the
effects of berberine, at the concentrations used in this study, were
not due to cytotoxicity (Table 1).
BERBERINE EFFECTS ON APICAL MEMBRANE Cl− CONDUCTANCE AND
BASOLATERAL Na+–K+-ATPase ACTIVITY AND K+ CONDUCTANCE
Nystatin, added to the basolateral bathing solution of T84 mono-
layers increased the apicalmembraneCl− speciﬁc current ICl from
3± 1 to 14± 2μA·cm−2 (n = 6), this likely reﬂects a constitutively
active apical membrane Cl− conductance. Subsequent addition of
forskolin (10μM) further increased the ICl to 88± 12μA·cm−2.
Treatment of T84 cell monolayers with berberine (300μM) on
either apical or basolateral bath for 15 min had no effect on either
basal or forskolin-activated apical membrane ICl (Table 2).
The addition of amphotericin B to the apical bathing solu-
tion containing 25 mM Na+ increased the basolateral membrane
Na+ speciﬁc pump current INa from 3± 1 to 16± 3μA·cm−2
(n = 6). Under these conditions, the amphotericin-induced INa
was completely inhibited by 100μM ouabain. When T84 mono-
layers were treated with berberine (300 μM) for 10 min, the
Table 1 | Effect of berberine on transepithelial resistance.
Time (hours) R t, Ω·cm2
Vehicle Berberine 100μM Berberine 300μM
0 1302± 212 1235± 205 1301± 182
1 1287± 234 1198± 192 1246± 235
2 1176± 187 1099± 210 1155± 211
Transepithelial resistance (Rt) was calculated using Ohms law by measuring the
ISC resulting from 5s square voltage pulses (2 or 4mV) imposed across the
monolayer. Values are mean±SEM; n= 8 for each group.
Table 2 | Berberine effect on membrane conductances.
Treatment ICl (μA/cm2) INa (μA/cm2) IK (μA/cm2)
Basal 14± 2 16± 3 53± 4
Basal+ berberine 12± 3 13± 3 9± 2**
Forskolin 88± 12 – 94± 2
Forskolin+ berberine 84± 10 – 15± 4**
Forskolin (10 (M) was added to stimulate CFTR and cAMP-dependent K( conduc-
tance. Berberine (300 (M) was added to the basolateral bath.The berberine effect
was measured 15min after the drug addition. n= 6 for each group, **P< 0.05.
amphotericin-induced INa was not different from that of vehicle
controls (Table 2).
When amphotericin B was added to the apical bath in the
presence of an apical to basolateral K+ gradient (80:5 mM)
and basolateral ouabain (100 μM), the IK immediately began
to increase and reached maximal levels within 15 min (from
5± 3 to 53± 4μA·cm−2; n = 6). In these conditions, IK was
almost completely inhibited by addition of BaCl2 (2 mM), chro-
manol 293B (10μM), or HMR-1556 (500 nM) to the basolateral
bath (Figure 2A). When monolayers were treated with berber-
ine (300μM), IK was rapidly inhibited (53± 4 to 9± 2μA·cm−2;
FIGURE 2 | Effect of berberine on basolateral K+ current (IK) across
apically permeabilizedT84 cell monolayers. (A) Effect of KCNQ1 channel
inhibitors on IK in T84 cell monolayers. Amphotericin B (10μM) was added
to apical bath after ouabain (100μM) was added to basolateral bath. BaCl2
(2mM), chromanol 293B (10μM), or HMR-1556 (500 nM) were added to
the basolateral bath. Values were measured at the point of maximal
inhibition of IK by each inhibitor. (B) Short-circuit currents recording of the
effect of berberine (300μM, ﬁlled circles) on IK across T84 cells monolayers
compared to a vehicle control (DMSO 0.05%, open circles). Drugs were
added at arrow and remained in the bathing solutions throughout the
experiment. Values are mean±SEM, **P < 0.01 compared to controls,
n= 6 for each group. (C)The concentration dependence of the inhibitory
effect of berberine on basolateral membrane K+ current showed a
half-maximal inhibition at 150μM.
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P< 0.01, n = 6; Figure 2B) with half-maximal inhibition pro-
duced at a concentration of 150 μM (Figure 2C).
BERBERINE EFFECTS ON WHOLE-CELL POTASSIUM CURRENTS IN T84
CELLS
Berberine produced a strong inhibitory effect on forskolin-
activated basolateral membrane IK in T84 monolayers (Table 2).
The effect of berberine on cAMP-stimulatedwhole-cell currents in
T84 cellswas examined (Figure 3A). Forskolin (10μM)stimulated
a mean maximal increase in whole-cell current of 359 ± 71 pA
(at Vp=+100 mV; n = 7, P < 0.001). Berberine (100 μM) addi-
tion to isolated T84 cells reduced the forskolin-activated cur-
rent by 68% (corresponding to a reduction of 245 ± 44 pA (at
FIGURE 3 | (A) Current/voltage relationships illustrating the effect of
berberine (100μM) on the increase in whole-cell current stimulated by
forskolin (10μM) in T84 cells. Traces are control (◦), forskolin (), and
forskolin+ berberine (). Data are mean±SEM (*P < 0.01 between the
forskolin-stimulated current and berberine, n = 7). (B) Current/voltage
relationships illustrating the effect of chromanol 293B (10μM) on the
increase in whole-cell current stimulated by forskolin (10μM) in T84 cells.
Traces are control (◦), forskolin (), and forskolin+ chromanol 293B ().
Data are mean±SEM (*P < 0.01 between the forskolin-stimulated current
and chromanol 293B, n = 3).
Vp=+100 mV, n = 7, P < 0.01). Consistent with the increase in
whole-cell current, forskolin-stimulated an increase in the chord
conductance at +100 mV (γ+100) from 1.7± 0.3 to 5.2± 0.4 nS
(P < 0.001, n = 7), which was reduced to 2.8± 0.2 nS (P < 0.01,
n = 7) following treatment with berberine.
The identity of the K+ channels underlying the current stimu-
latedby forskolin and inhibitedbyberberinewas investigatedusing
a variety of K+ channel blockers. Chromanol 293B (10μM) com-
pletely inhibited the forskolin-stimulated current below the level of
the control current measured prior to the addition of forskolin (at
Vp +100 mV: forskolin= 665± 193 pA; forskolin+ chromanol
293B= 86± 51 pA; P < 0.05, n = 3; Figure 3B). Superfusion with
chromanol 293B also reduced the forskolin-induced chord con-
ductance at +100 mV from 7.2± 1.4 to 1.2± 0.5 nS (P < 0.05,
n = 3). Other speciﬁc K+ channel inhibitors (of large and small
conductance, Ca2+-dependent K+ channels) such as iberiotoxin
(BK, 200 nM), apamin (SK, 500 nM), and TRAM-34 (KCNN4,
500 nM) did not affect the forskolin-induced whole-cell K+
currents.
BERBERINE EFFECT ON PROTEIN KINASES ACTIVITY IN T84 CELLS
PKCα activation was assessed by probing with a speciﬁc antibody
tophospho-Ser657. Berberine treatment increasedPKCαphospho-
rylation levels at 5 and 10 min with fold increases of 6.4 ± 0.8 and
7.4± 1.8 respectively (n = 3, P< 0.01) compared to vehicle con-
trols (Figure 4A). PKCδ activity was measured using an antibody
speciﬁc to phospho-Ser643. Berberine treatment had no effect on
PKCδ phosphorylation levels (5 min 1.1 ± 0.1; 10 min 0.9± 0.1;
n = 3) compared to vehicle controls within the time period assayed
(Figure 4B). These results show that berberine selectively activates
the classical PKCαwithno effect on the novel PKCδ. Berberine pre-
treatment activated PKA at 10 min with a fold increase of 2.2 ± 0.1
compared to vehicle controls (n = 3, P< 0.001; Figure 4C). Pre-
treatment for 10 min with 100μM HBDDE, a selective PKCα
inhibitor at this concentration (Kashiwada et al., 1994), prevented
berberine-induced PKA activation (1.0± 0.1; n = 3; Figure 4C).
This result indicates that PKA is activated in response to berberine
and is downstream to PKCα activation.
Activation of p38MAPKwas assessed by probingwith a speciﬁc
antibody to phospho-Thr180/Tyr182. Berberine treatment induced
p38 MAPK phosphorylation at 5 min with a fold increase of
1.8± 0.02 (n = 3, P< 0.05; Figure 5A). The activity of p42/p44
MAPK was measured using an antibody speciﬁc to phospho-
Thr202/Tyr204. Treatment with berberine had no effect on basal
p42/p44 MAPK phosphorylation levels compared to vehicle con-
trols (0.8± 0.3, P< 0.04, n = 4) within the time points assayed
(Figure 5B). However, pre-treatment of the cells with berber-
ine for 5 min inhibited activation of p42/p44 MAPK by epi-
dermal growth factor (EGF 100 ng·ml−1) with similar potency
to that of PD98059 (20 μM), a speciﬁc MEK1 inhibitor that
prevent receptor-mediated activation of p42/p44 MAPK, (EGF
10.3± 1.1; berberine+ EGF 1.6± 0.7; PD98059+ EGF 0.6± 0.1;
n = 4, P< 0.01; Figure 5B). These results conﬁrm that berberine
selectively activates the p38 MAPK isoform but does not acti-
vate p42/p44 MAPK isoforms. Moreover, berberine prevents the
EGF-induced activation of p42/p44 MAPK.
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FIGURE 4 | Berberine effect on PKC isoforms and PKA activity inT84
cells. (A) Representative blot of PKCα phosphorylation levels at Ser657 in
cellular extracts fromT84 cells after berberine treatment (300μM) for 5 and
10min compared to vehicle controls. (B) Representative blot of PKCδ
phosphorylation levels at Ser643 in cellular extracts fromT84 after berberine
treatment (300μM) cells for 5 and 10min compared to vehicle controls.
Beta-actin was used as an internal control for protein loading. The graphs
represent densitometric analysis of PKC blots or PKA activity assays. Values
are given as fold changes in PKC phosphorylation (activation) or PKA activity
respect to an untreated control. Values are displayed as mean±SEM (n = 3
for each group, **P< 0.01). (C) Representative blot of PKA phosphorylation
levels in cellular extracts fromT84 after berberine treatment (300 μM) cells for
10 min compared to vehicle controls and cells pretreated for 10 min with
100 μM HBDDE, a selective PKCα inhibitor.
BERBERINE INHIBITION OF cAMP-STIMULATED Cl− SECRETION IS
MEDIATED BY PROTEIN KINASES
To assess the role of berberine-induced protein kinase activation
on its antisecretory effect, T84 monolayers mounted in Ussing
chambers were pre-treated with speciﬁc kinase inhibitors. Treat-
ment of T84 monolayers with the PKCα inhibitor HBDDE and
the speciﬁc p38 MAPK inhibitor SB202190 (10 μM) had no effect
on basal or forskolin-stimulated I SC. However, HBDDE signiﬁ-
cantly reduced the inhibitory effect of berberine on I SC by 65± 7%
(Figure 6A). SB202190 also reduced the effect of berberine but
only by 14± 5% (Figure 6A). Co-incubation with both inhibitors
inhibited the effect of berberine by 82± 4% suggesting parallel
and synergistic signaling pathways. In contrast, inhibitors of PKCδ
(rottlerin 10μM) and p42/p44 MAPK (PD98059 20μM) failed
to prevent the antisecretory effect of berberine. Figure 6B shows
percentage of inhibition of the berberine antisecretory action on
forskolin-stimulated I SC by several kinase inhibitor treatments.
Berberine pre-treatment increased the association of PKCα
with the KCNQ1 channel at 5 min with a fold increase of 2.4± 0.1
(n = 3, P< 0.05; Figure 7A). Upon activation, PKA catalytic sub-
units (PKAcI) dissociate from their regulatory subunits and inter-
act with their substrates. Berberine treatment increased PKAcI
association with the KCNQ1 channel with a fold increase of
2.2± 0.4 (n = 3, P< 0.05; Figure 7B). These experiments demon-
strate the association of two kinases, PKCα and PKAcI, with the
KCNQ1 channel upon treatment with berberine.
DISCUSSION
The results from this study show that the plant alkaloid berber-
ine inhibits cAMP-dependent Cl− secretion through a kinase-
dependent inhibition of the KCNQ1 potassium channel located at
the basolateral membrane of human colonic T84 cells. These data
identify the ion channel target of berberine to produce inhibition
of transepithelial Cl− secretion which we described in early stud-
ies in human colonic epithelia (Taylor et al., 1999). Taken together
our results are consistent with the hypothesis that blockade of Cl−
secretion by berberine in colonic epithelia is secondary to blockade
of basolateralmembraneK+ channels involved in cAMP-regulated
Cl− secretory pathways.
At least two types of K+ channels are present in T84 cells
(Barrett and Keely, 2000; Kunzelmann and Mall, 2002). One chan-
nel is activated by agents that elevate cytosolic Ca2+ and has been
identiﬁed as the KCNN4 channel (Warth et al., 1999). A separate
K+ channel is activated by cAMP-dependent agonists. Electro-
physiological and pharmacological studies have demonstrated this
K+ conductance to correspond to the KCNQ1 channel (Schroeder
et al., 2000) and this channel has been shown to be rate-limiting
for secretion in colon (Preston et al., 2010). In our study, berberine
signiﬁcantly reduced the basolateral membrane K+ conductance.
This conductance was stimulated by the cAMP-dependent agonist
forskolin and was sensitive to basolateral addition of Ba2+, a non-
speciﬁcK+ channel blocker, and chromanol 293B,andHMR-1556,
two speciﬁc KCNQ1 channel blockers, suggesting the main com-
ponent of the basolateral K+ conductance is composed of current
ﬂow through KCNQ1 channels. Similarly, berberine inhibited a
cAMP-stimulated and chromanol 293B-sensitive whole-cell con-
ductance, suggesting berberine inhibits KCNQ1 channels. Berber-
ine had no effect on the apical Cl− conductance nor did it affect
the basolateral Na+–K+-ATPase pump activity determined as
ouabain-sensitive basolateral membrane Na+ current. Therefore,
this data suggests berberine exerts its antisecretory effect primarily
by inhibiting KCNQ1 channels, thus, decreasing K+ recycling at
the basolateral membrane.
Recent studies have examined the effects of berberine on pro-
tein kinase activity in several tissues. These reports have shown
that the antihyperglycemic activity of berberine is mediated by
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FIGURE 5 | Berberine effect on MAPK signaling inT84 cells. (A)
Representative blot of p38 MAPK phosphorylation levels at Thr180/Tyr182 in
cellular extracts fromT84 cells after berberine treatment (300μM) for 5 and
10min compared to vehicle controls. (B) Representative blot of p42/p44
MAPK phosphorylation levels at Thr202/Tyr204 in cellular extracts fromT84
cells after berberine treatment (300μM) for 5 and 10min compared to
vehicle controls. T84 cells were treated with EGF (100 ng·ml−1) for 5min to
stimulate p42/p44 MAPK phosphorylation. PD98059 (20μM) was added
15min prior EGF-treatment. B-actin was used as an internal control for
protein loading. The graphs represent densitometric analysis of blots.
Values are given as fold changes in MAPK phosphorylation (activation)
respect to an untreated control. Values are displayed as mean±SEM (n = 3
for each group, *P < 0.05, ***P< 0.001).
activationof p38MAPKandAMP-activatedprotein kinase (Cheng
et al., 2006; Lee et al., 2006). The antiproliferative activity of
berberine has been reported to be mediated by inhibition of
cyclin-dependent kinases and theMAPKpathway in several tissues
(Liang et al., 2006; Mantena et al., 2006). In T84 cells, no effect
on basal p42/44 MAPK activity was observed, however, berber-
ine did prevent EGF-induced activation of p42/44 MAPK. Several
studies have described the ability of EGF receptor-mediated sig-
naling in regulating Cl− secretion though MAPK (Bertelsen et al.,
2004). Therefore, it is possible that berberine may also reduce
Cl− secretion by interfering with the EGF signaling. Also, the
inhibitory effect of berberine on EGF signaling may be relevant
in the antiproliferative action of berberine.
FIGURE 6 | Role of protein kinases on the antisecretory effect of
berberine. (A) Short-circuit current recordings in T84 cell monolayers of the
effect of protein kinases inhibitors on the antisecretory effect of berberine
(300μM). Cells were pre-incubated for 15min with HBDDE 100μM (),
SB202190 10μM (◦), or vehicle DMSO 0.05% (•). (B) Mean±SEM (n = 6)
change in total ISC caused by preincubation with several kinase inhibitors on
the antisecretory effect of berberine on forskolin-stimulated ISC. Values are
mean±SEM, n = 6, *P < 0.05, **P < 0.01 compared to controls.
Berberine activated p38 MAPK, PKA, and PKCα. Activation of
PKAwas observed to be dependent onPKCα activity, and this is the
ﬁrst study to demonstrate berberine-induced activation of PKA
andPKCα. Upon activation by berberine, both kinaseswere shown
to transiently associatewith theKCNQ1 channel even though both
kinases remained activated for a longer period. Several studies
have demonstrated regulation of K+ channels by protein kinases.
We have previously shown that estrogen causes a female-gender
speciﬁc inhibition of KCNQ1 channels in rat colonic crypts, pro-
ducing an antisecretory response which is also dependent on PKA
activation and association with the KCNQ1 channel (O’Mahony
et al., 2009). Therefore, we investigated the role of berberine-
induced kinase activity on the antisecretory effect of berberine.
Using speciﬁc kinase inhibitors we demonstrated that the antise-
cretory effect of berberine could be halved by the PKCα inhibitor
HBDDE. Pre-treatment with SB202190, a speciﬁc inhibitor of p38
MAPK,also signiﬁcantly decreased the effect of berberineon secre-
tion, although to a much lesser degree. In agreement with these
ﬁndings, several studies have shown that the phorbol ester PMA
inhibits the basolateral K+ conductance of T84 cells and that this
effect reduces transepithelial Cl− secretion (Matthews et al., 1993;
Reenstra, 1993). The molecular mechanism by which berberine-
induced activation of PKCα and p38 MAPK inhibits basolateral
KCNQ1 channels in T84 is an important goal of future studies.
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FIGURE 7 | Berberine effect on protein kinase association with KCNQ1
channel. (A) Representative blot of PKCα association with the KCNQ1
channel in response to berberine (300μM) in T84 cells. (B). Representative
blot of PKACI association with the KCNQ1 ion channel in response to
berberine (300μM) in T84 cells. Total KCNQ1 pools were
immunoprecipitated from total cellular lysates using an antibody speciﬁc to
KCNQ1. Associated PKCα and PKAcI were quantiﬁed byWestern blot
analysis. The graphs represent densitometric analysis at speciﬁc time
points of berberine treatment compared to vehicle controls. Values are
given as fold changes in kinase association with KCNQ1 respect to an
untreated control. Values are displayed as mean±SEM (n = 3 for each
group, *P < 0.05, ***P< 0.001).
Onepossibility to be considered is a change in the phosphorylation
state of the channel protein, which is an important determinant of
K+ channel activity (Kathöfer et al., 2003; Kurokawa et al., 2003;
Li et al., 2004) and which we have shown to mediate the estrogen-
induced inhibition of KCNQ1 in rat colonic crypts (O’Mahony
et al., 2007).
The present study has shown activation of PKA by berber-
ine. It is well documented that activation of these enzyme lead
to an increase in CFTR activity in colonic crypts (Schultheiss
and Diener, 1998; Barrett and Keely, 2000; Kunzelmann and Mall,
2002). However, in this study berberine did not affect the apical
Cl− current but had an overall inhibitory effect on Cl− secretion.
This paradox of activation of PKA without activation of CFTR
can be explained if we consider that the cAMP–PKA pathway is
tightly regulated at several levels to maintain speciﬁcity in the mul-
titude of signal inputs (Tasken and Aandahl, 2004; Cooper, 2005).
Ligand-induced changes in cAMP concentration vary in duration,
amplitude, and localization into the cell, and cAMPmicrodomains
are shaped by adenylyl cyclases that form cAMP as well as phos-
phodiesterases that degrade cAMP. Different PKA isozymes with
distinct biochemical properties and cell-speciﬁc expression con-
tribute to cell and organ speciﬁcity. Activated kinase anchoring
proteins target PKA to speciﬁc substrates and distinct subcellu-
lar compartments providing spatial and temporal speciﬁcity for
mediation of biological effects channeled through the cAMP–PKA
pathway (McConnachie et al., 2006). Therefore, the activation of
PKA by berberine does not necessarily imply phosphorylation and
activation of CFTR located in the apical membrane.
Berberine is freely permeable across human intestinal epithe-
lia and its absorption is signiﬁcantly increased by P-glycoprotein
inhibitors (Pan et al., 2002). It is possible that berberine interacts
with a known receptor to effect its antisecretory action. Recently
berberine has been shown to affect the activity of sex steroid
receptors including the androgen receptor (antagonist) in prostate
cancer cells (Li et al., 2011) and the pregnane X receptor (ago-
nist) in HepG2 cells (Yu et al., 2011). Berberine has been shown
to enhance the anticancer effect of estrogen receptor antagonists
on human breast cancer cells (Liu et al., 2009). The only known
receptor-mediated inhibition of KCNQ1 channels in intestine is
the estrogen receptor (O’Mahony et al., 2007). 17-B estradiol (E2)
inhibits Cl− secretion via PKC and PKA dependent phosphoryla-
tion of the KCNQ1:KCNE3 K+ channels in colonic crypts and
berberine displays a remarkably similar mechanism of antise-
cretory action to E2 (both inhibit KCNQ1 channels by protein
kinase phosphorylation and neither molecule inhibits CFTR). It is
possible that berberine modulates estrogen receptor signaling in
intestinal cells to inhibitKCNQ1channels similar toE2. The chem-
ical structure of berberine is similar to the novel GPR30 receptor
agonist G-1 and this orphan estrogen receptor may also be a target
of berberine. A hypothetical schema of the antisecretory action of
berberine in intestinal epithelium is presented in Figure 8.
The ability of berberine to inhibit salt and water secretion from
native intestinal tissue, as evidenced by blockade of stimulated
I SC in rabbit and rat colon in vitro, raises the distinct possibility
that berberine and related compounds may display utility in the
clinical treatment of secretory diarrhoeas. High doses of berber-
ine have already been administered orally to humans (Rabbani
et al., 1987; Tang and Eisenbrand, 1992), and can be therapeuti-
cally safe over the long term. In support of this view, we found
that berberine had no detectable effect on the transepithelial resis-
tance of T84 monolayers over a 2-h treatment period. Thus,
berberine may inhibit basal and cAMP-induced ﬂuid secretion
from intestine without affecting the net transport and absorption
of nutrient substrates or absorptive capacity. In fact, berberine
has been shown to stimulate Na+ absorption (Tai et al., 1981).
Unlike most antidiarrheals, berberine exhibits several pharma-
cological actions useful to the treatment of secretory diarrhea.
Firstly, it reduces the cause of infection via its antimicrobial activ-
ity. Secondly, berberine increases stool transit time through the
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FIGURE 8 | Hypothetical schema of the antisecretory action of
berberine in intestinal epithelium. Berberine activates p38 MAPK, PKCα
and PKA to phosphorylate the KCNQ1:KCNE3 K+ channel causing the
channel to become inactive either through closure or removal from the
plasma membrane. Inhibition of basolateral K+ channel reduces the
electrical driving force for Cl− exit across the apical membrane through
CFTR and calcium-activated Cl− channels. The receptor transducing the
response to berberine may be the estrogen receptor or GPR30/GPCR as
previously described for similar antisecretory and rapid protein kinase
responses to estrogen in the intestine.
intestine via its antimotility action. Finally, as shown here, berber-
ine decreases basolateral membrane K+ recycling, thus reducing
the electrical driving force for whole secretory process in the
enterocytes.
Other laboratories have also explored the use of K+ chan-
nel blockers to inhibit epithelial Cl− secretion. The antifungal
antibiotic, clotrimazole, has been shown to prevent ﬂuid and elec-
trolyte secretion in rabbit and mouse intestine triggered by Ca2+-
and cAMP-mediated agonists via speciﬁc inhibition of basolat-
eral K+ conductances (Rufo et al., 1997). Furthermore, levamisole
(and other phenylimidazothiazoles) inhibits Ca2+- and cAMP-
activated Cl− secretion in T84 cell monolayers and isolated human
distal colon, apparently by blocking basolateral K+ channels (Mun
et al., 1998). Greger and colleagues noted that a group of chro-
manol compounds selected from agents screened for the ability
to block I SC in isolated rabbit colon turned out to be ineffective
as Cl− channel blockers, but effective as blockers of K+ channel
activity elicited by cAMP-dependent agonists. The most potent of
these was chromanol 293B (Lohrmann et al., 1995), which here
was shown to block KCNQ1 channels in T84 cells. Chromanol
293B has been described to block CFTR currents when expressed
in Xenopus oocytes (Bachmann et al., 2001) but this has not been
observed in native epithelia. In our study, the KCNQ1 inhibitors,
chromanol 293B, and HMR-1556 were added from the basolateral
side without affecting apical Cl− currents. The inhibitory effects
of these molecules on transepithelial Cl− secretion is indirect via
block of KCNQ1 channels. Like chromanol 293B, berberine also
reduced the basolateral K+ current activated by cAMP-dependent
agonists. Our ﬁnding that berberine has a marked inhibitory effect
on basolateral KCNQ1 channel current in T84 cells highlights this
component of the intestinal Cl− secretory process as a target for
new antidiarrhoeal strategies. Identiﬁcation of the mechanism of
kinase regulation of basolateral K+ channels in colonic epithelia
and a better understanding of the signaling processes involvedmay
provide a basis for the development of new antisecretory drugs
with greater potency and speciﬁcity.
In summary, based on the results of our previous studies in rat
colon in vitro and the present studies in T84 cells monolayers, we
propose that the effect of berberine on chloride ion secretion in
intestine is mediated by a protein kinase-dependent reduction in
basolateral KCNQ1 channel activity.
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